<DOC>
	<DOCNO>NCT01485965</DOCNO>
	<brief_summary>The primary purpose study assess effect food upon pharmacokinetics ( PK ) SEN0014196 subject Huntington disease ( HD ) .</brief_summary>
	<brief_title>A Open-label Food Effect Study With SEN0014196 Subjects With Huntington Disease</brief_title>
	<detailed_description>In addition pharmacokinetic endpoint , study assess safety tolerability 100 mg daily ( qd ) dose SEN0014196 14 day subject HD explore potential biomarkers use subsequent Phase 2/3 study .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<criteria>Subjects early mid HD , i.e. , genetically confirm HD ( cytosine , adenine , guanine [ CAG ] codon repeat length ≥ 36 ) , motor sign HD , Total Functional Capacity Subscale Score ( TFC ) ≥ 7 Body mass index 18 31 kg/m2 inclusive All subject must body weight great 50 kg Female subject must surgically sterile , postmenopausal , willing practice highly effective method contraception . All female participant must nonlactating nonpregnant . Male subject must agree use reliable method birth control study 3 month last dose study drug . Capable provide informed consent MMSE ≥24 Subjects must livein competent observer Participation study receive investigational drug within 30 day Baseline Visit Any prior concomitant use compound suspect interfere protein acetylation Any concomitant use medication know inhibitor CYP450 enzymes substrates CYP1A2 time enrollment Suicide risk , determine meeting either follow criterion : ) suicide attempt within past year suicidal ideation within 60 day Screening Visit ; b ) Significant risk suicide , judge Investigator Subjects MMSE &lt; 24 Subjects presence clinically significant psychosis and/or confusional state , opinion Investigator Subjects clinically significant laboratory ECG abnormalities Screening Baseline Subjects clinically relevant hematologic , hepatic , cardiac , renal disease Subjects current past ( within last 12 month ) history epilepsy seizures A medical history infection human immunodeficiency virus , hepatitis C , and/or hepatitis B Subjects history substance abuse within past 12 month Female subject pregnant breastfeed Known allergy ingredient study drug A history malignancy type within 2 year prior Screening . A history surgicallyexcised nonmelanoma skin cancer permit . Any relevant condition , behavior , laboratory value , concomitant medication , opinion Investigator , make subject unsuitable entry study</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Huntington Disease</keyword>
	<keyword>Basal Ganglia Diseases</keyword>
	<keyword>Brain Diseases</keyword>
	<keyword>Central Nervous System Diseases</keyword>
	<keyword>Nervous System Diseases</keyword>
	<keyword>Dementia</keyword>
	<keyword>Chorea</keyword>
	<keyword>Dyskinesias</keyword>
	<keyword>Movement Disorders</keyword>
	<keyword>Heredodegenerative Disorders , Nervous System</keyword>
	<keyword>Neurodegenerative Diseases</keyword>
	<keyword>Genetic Diseases , Inborn</keyword>
	<keyword>Cognition Disorders</keyword>
	<keyword>Mental Disorders</keyword>
</DOC>